All Access

Biotech Deals

Biotech Deals Alert

Alert

WhiteLab Genomics, a genomic medicine developer, raised a $26 million Series B, CEO David Del Bourgo tells Axios Pro exclusively.

Follow the money: AVP led the round, joined by Omnes Capital, Yaday Health, Blast Club and Debiopharm Innovation Fund.

WhiteLab has raised about $37 million to date and has two to three years of runway, Del Bourgo says.

How it works: WhiteLab's proprietary Alfred platform uses AI to design viral and non-viral delivery vehicles and programmable genetic payloads.

The designs are then experimentally validated and tested in vivo to identify drug candidates.

The company says its process helps reduce the time and cost of developing genomic medicines.

Zoom in: Rather than taking assets to the clinic, WhiteLab has about 15 revenue-generating partnerships with external biotechs and Big Pharma companies, including Sanofi.

Other partners include Cytiva, Debiopharm, the University of Massachusetts, the Vision Institute in Paris and the Paris Brain Institute.

What they're saying: "We specialize in what we're very good at doing … bringing preclinical assets to their highest level of validation as possible, and then partnering with pharma," Del Bourgo says.

"You have the best of both worlds because you are paid for providing the platform, and you are paid in case of success (in) the drug development process," says AVP managing partner François Robinet.

Behind the scenes: Del Bourgo says he is open to being acquired, and that WhiteLab has been approached by potential buyers, but would also consider a U.S. IPO.

Zoom out: The life sciences and biotech fundraising environment has improved this year after a multiyear slump.

By the numbers: Biopharma VC funding topped $10 billion in Q2 — only the third time since early 2022, per PitchBook data.

Exclusive: WhiteLab Genomics raises $26M Series B for AI-designed genomic medicines

WhiteLab plans to expand its U.S. operations.

Illustration of a double helix made out of a $100 bill.

WhiteLab Genomics, a genomic medicine developer, raised a $26 million Series B, CEO David Del Bourgo tells Axios Pro exclusively.Follow the money: AVP led the round, joined by Omnes Capital, Yaday Health, Blast Club and Debiopharm Innovation Fund.

topics

politics-policy

epstein-files

donald-trump

2026-midterm-elections

immigration

behind-the-curtain

race-and-equity

technology

privacy-tech-regulation

automation-and-ai

tiktok-news

big-tech

social-media

cybersecurity

economy

social-security

inflation

tariffs

federal-reserve

transportation

business

c-suite

retail-news

media

elon-musk

dealmaking

health

rfk-jr

drug-prices

axios-explains-abortion

public-health

world

israel

axios-explains-ukraine

iran

russia

china

energy-climate

nuclear-energy

climate-energy-policy

climate-change

extreme-weather

alternative-energy

electric-vehicles

science

emerging-tech

biomedicine

newsletters

charlotte

salt-lake-city

denver

fort-lauderdale

cincinnati

scottsdale

boulder

kansas-city

austin

chicago

dallas

detroit

atlanta

indianapolis

nashville

nw-arkansas

columbus

hollywood

washington-dc

north-of-cincy

mesa

richmond

san-francisco

boston

des-moines

houston

phoenix

miami

philadelphia

seattle

new-orleans

colorado-springs

huntsville

raleigh

san-antonio

twin-cities

pittsburgh

san-diego

tampa-bay

portland

cleveland

arapahoe

douglas

axios-local

axios-pro

axios-live

the-axios-show

Exclusive: WhiteLab Genomics raises $26M Series B for AI-designed genomic medicines

What to read next